Latest news

• Novartis claims FDA breakthrough status for leukaemia treatment

  Also waiting in the wings could be volasertib from Boehringer Ingelheim, which is currently in phase III clinical trials, and Pifzer's Mylotarg, which would be reintroduced to the market after

• Boehringer and Philogen collaborate on acute myeloid leukaemia

  Treatment options for AML are still somewhat limited, however at the end of last year Pfizer's Mylotarg (gemtuzumab ozogamcin) also showed itself to significantly improve overall survival compared to best

• ASH: Pfizer eyes re-launch of Mylotarg

  ASH: Pfizer eyes re-launch of Mylotarg. Data supports drug's use in acute myeloid leukaemia. ... We are engaging in discussions with the FDA and other health authorities to determine the best path forward for Mylotarg", he added.

• AZ buys into ADC sector with $440m Spirogen deal

  After a false start in 2000 with the launch and subsequent withdrawal from the market of Mylotarg (gemtuzumab ozogamicin) from Wyeth (now Pfizer), the ADC field has started to gather pace,

• ­Pfizer signs $635m deal with CytomX for cancer ADCs

  The first ADC to reach the market was Pfizer acquisition Wyeth's Mylotarg (gemtuzumab ozogamicin) for acute myeloid leukaemia in 2000, but it took another 10 years before it was joined